<DOC>
	<DOCNO>NCT01549834</DOCNO>
	<brief_summary>This efficacy safety study evaluate new treatment subject mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Evaluate Efficacy Safety ABT-126 Subjects With Mild Moderate Alzheimer 's Disease Stable Doses Acetylcholinesterase Inhibitors</brief_title>
	<detailed_description>This Phase 2 study design evaluate efficacy safety ABT-126 approximately 420 adult mild moderate Alzheimer 's disease take stable dos acetylcholinesterase inhibitor . Subjects randomize one two ABT-126 dose arm placebo 24-week treatment period .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>The subject caregiver must voluntarily sign date inform consent . If subject capacity provide inform consent , full informed consent must obtain subject 's representative assent must obtain subject . The subject male female age 55 90 year , inclusive , Screening Visit 1 . Main Inclusion ( Continued ) : The subject meet Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD . The subject must receive stable dose AChEI ( donepezil rivastigmine ) least 90 day prior Screening Visit 1 . The subject MiniMental Status Examination ( MMSE ) total score 12 24 , inclusive , Screening Visit 1 . The subject Cornell Scale Depression Dementia ( CSDD ) score ≤ 10 Screening Visit 1 . The subject Modified Hachinski Ischemic Scale ( MHIS ) score ≤ 4 Screening Visit 1 . With exception diagnosis mildtomoderate Alzheimer 's disease presence stable medical condition , subject general good health , base upon result medical history , physical examination , vital sign , laboratory profile , 12lead electrocardiogram ( ECG ) . The subject identify , reliable caregiver provide support ensure compliance study medication procedure , provide accurate information subject 's status study . The subject take galantamine memantine within 60 day prior Screening Visit 1 . The subject receive excluded concomitant medication . The subject clinically significant abnormal laboratory value Screening Visit 1 determine investigator . The subject history significant neurologic disease Alzheimer 's disease include Parkinson 's disease , multiinfarct vascular dementia , Huntington 's disease , normal pressure hydrocephalus , progressive supranuclear palsy , multiple sclerosis , seizure , mental retardation history significant head trauma follow persistent neurologic deficit know structural brain abnormality . In opinion investigator , subject clinically significant uncontrolled medical psychiatric illness .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>